Differences in Drug Sensitivity among Tumor Cells from Parental Tumors, Selected Variants, and Spontaneous Metastases

Cancer Research

Volumn 41, Issue 8, 1981, Pages 3058-3064

  Tsuruo, Takashi ^a   Fidler, Isaiah J ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMSACRINE; BLEOMYCIN; DACARBAZINE; DOXORUBICIN; IMIDAZOLE; VINCRISTINE; VINDESINE;

ANIMAL EXPERIMENT; CANCER CELL; CANCER CHEMOTHERAPY; CANCER GROWTH; DRUG SENSITIVITY; FIBROSARCOMA; HUMAN CELL; IN VITRO STUDY; MELANOMA; METASTASIS; THERAPY;

ANIMAL; ANTINEOPLASTIC AGENTS; CLONE CELLS; DOSE-RESPONSE RELATIONSHIP, DRUG; FIBROSARCOMA; HUMAN; MELANOMA; MICE; NEOPLASM METASTASIS; NEOPLASMS, EXPERIMENTAL; SUPPORT, NON-U.S. GOV'T; SUPPORT, U.S. GOV'T, P.H.S.;

EID: 0019454312     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: None     Document Type: Article

References (51)

1. Barranco, S. C., Drewinko, B., and Humphrey, R. M. Differential response by human melanoma cells to 1,3-bis-(2-chloroethyl)-1 -nitrosourea and bleomycin. Mutat. Res., 19: 277–280, 1973.
2. Barranco, S. C., Haenelt, B. R., and Gee, E. L. Differential sensitivities of five rat hepatoma cell lines to anticancer drugs. Cancer Res., 38: 656–660, 1978.
3. Barranco, S. C., Ho, D., Drewinko, B., Romsdahl, M. M., and Humphrey, R. M. Differential sensitivities of human melanoma cells grown in vitro to arabinosylcytosine. Cancer Res., 32: 2733–2736, 1972.
4. Baylin, S. B. Clonal selection and heterogeneity of human solid neoplasms. In: I. J. Fidler and R. J. White (eds.), Design of Models for Testing Cancer Therapeutic Agents. New York: D. Van Nostrand Co., in press, 1981.
5. Baylin, S. B., Weisburger, W. R., Eggleston, J. C., Mendelsohn, G., Beaven, M. A. Abeloff, M. D., and Ettinger, D. S. Variable content of histaminase. l-dopa decarboxylase and calcitonin in small-cell carcinoma of the lung. Biologic and clinical implications. N. Engl. J. Med., 299: 105–110, 1978.
6. Biorklund, A., Hakansson, L., Stenstam, B., Trope, C., and Akerman, M. Heterogeneity of non-Hodgkin's lymphomas as regards sensitivity to cytostatic drugs. An in vitro study. Eur. J. Cancer, 16: 647–654, 1980.
7. Blum, R. H., and Carter, S. K. Adriamycin, a new anticancer drug with significant clinical activity. Ann. Intern. Med., 80: 249–259, 1974.
8. Blum, R. H., Carter, S. K., and Agre, K. A clinical review of bleomycin—a new antineoplastic agent. Cancer (Phila.), 31: 903–914, 1973.
9. Brennan, M. J., Donegan, W. L., and Appleby, D. E. The variability of estrogen receptors in metastatic breast cancer. Am. J. Surg., 137: 260–262, 1979.
10. Calabresi, P., Dexter, D. L., and Heppner, G. H. Clinical and pharmacological implications of cancer cell differentiation and heterogeneity. Biochem. Pharmacol., 28: 1933–1934, 1979.
11. Carter, S. K. Adriamycin, a review. J. Natl. Cancer Inst., 55: 1265–1274, 1975.
12. Carter, S. K., and Livingston, S. B. Plant products in cancer chemotherapy. Cancer Treat. Rep., 60: 1141-1156, 1976.
13. Chain, B. F., and Atwell, G. J. The experimental antitumor properties of three congeners of the acridylmethane-sulphonailide (AMSA) series. Eur. J. Cancer, 10: 539–549, 1974.
14. Comis, R. L. DTIC (NSC-45388) in malignant melanoma: A perspective. Cancer Treat. Rep., 60: 165-176, 1976.
15. Fidler, I. J. Tumor heterogeneity and the biology of cancer invasion and metastasis. Cancer Res., 38: 2651–2660, 1978.
16. Fidler, I. J., and Cifone, M. A. Properties of metastatic and nonmetastatic cloned subpopulations of an ultraviolet light-induced murine fibrosarcoma of recent origin. Am. J. Pathol., 97: 633–648, 1979.
17. Fidler, I. J., and Kripke, M. L. Metastasis results from preexisting variant cells within a malignant tumor. Science (Wash. D. C.) 197:893-895,1977.
18. Fidler, I. J., and Kripke, M. L. Biological variability within murine neoplasms. Antibiot. Chemother. (Basel), 28: 123–129, 1980.
19. Fidler, I. J., and Kripke, M. L. Tumor cell antigenicity, host immunity and cancer metastasis. Cancer Immunol. Immunother., 7: 201–205, 1980.
20. Fugmann, R. A., Anderson, J. C., Stolfi, R. L., and Martin, D. S. Comparison of adjuvant chemotherapeutic activity against primary and metastatic spontaneous murine tumors. Cancer Res., 37: 496–500, 1977.
21. Hakansson, L., and Trope, C. On the presence within tumors of clones that differ in sensitivity to cytostatic drugs. Acta Pathol. Microbiol. Scand Sect. A Pathol., 82: 35–40, 1974.
22. Hakansson, L., and Trope, C. Cell clones with different sensitivity to cytostatic drugs in methylcholanthrene-induced mouse sarcomas. Acta Pathol. Microbiol. Scand. Sect. A Pathol., 82: 41–47, 1974.
23. Hanna, N., and Fidler, I. J. Expression of metastic potential of allogeneic and xenogeneic neoplasms in young nude mice. Cancer Res., 41:438-443, 1981.
24. Hanna, N., and Fidler, I. J. Relationship between metastatic potential and resistance to natural killer cell-mediated cytotoxicity in three murine tumor systems. J. Natl. Cancer Inst., in press, 1981.
25. Hart, I. R. Selection and characterization of invasive variant of the B16 melanoma. Am. J. Pathol., 97: 587–600, 1979.
26. Heppner, G. H. The challenge of tumor heterogeneity. In: R. D. Bulbrook and D. J. Taylor (eds.), Commentaries on Research in Breast Disease, pp. 177–191. New York: Alan R. Liss, Inc., 1979.
27. Heppner, G. H., Dexter, D. L., DeNucci, T., Miller, F. R., and Calabresi, P. Heterogeneity in drug sensitivity among tumor cell subpopulations of a single mammary tumor. Cancer Res., 38: 3758–3763, 1978.
28. Heppner, G., and Miller, B. E. Biological variability of mouse mammary neoplasms. In: I. J. Fidler and R. J. White (eds.), Design of Models for Testing Therapeutic Agents. New York: D. Van Nostrand Co., in press, 1981.
29. Kerbel, R. S. Implications of immunological heterogeneity of tumours. Nature (Lond.), 280: 358–360, 1979.
30. Kripke, M. L. Guest editorial: Speculations on the role of ultraviolet radiation in the development of malignant melanoma. J. Natl. Cancer Inst., 63: 541-548,1979.
31. Kripke, M. L., Gruys, E., and Fidler, I. J. Metastatic heterogeneity of cells from an ultraviolet light-induced murine fibrosarcoma of recent origin. Cancer Res., 38: 2962–2967, 1978.
32. Legha, S. S., Gutterman, J. U., Hall, S. W., Benjamin, R. S., Burgess, M. A., Valdivieso, M., and Bodey, G. P. Phase 1 clinical investigation of 4’-(9-acridinylamino)methanesulfon-m-anisidine (NSC 249992), a new acridine derivative. Cancer Res., 38: 3712–3716, 1978.
33. Lotan, R. Different susceptibilities of human melanoma and breast carcinoma cell lines to retinoic acid-induced growth inhibition. Cancer Res., 39:1014-1019, 1979.
34. Lotan, R., and Nicolson, G. L. Heterogeneity in growth inhibition by fl-trans-retinoic acid of metastatic B16 melanoma clones and in v/Yo-selected cell variant lines. Cancer Res., 39: 4767–4771, 1979.
35. Miller, B. E., Miller, F. R., Leith, J., and Heppner, G. H. Growth interaction in vivo between tumor subpopulations derived from a single mouse mammary tumor. Cancer Res., 40: 3977–3981, 1980.
36. Oliverio, V. T. Derivatives of triazenes and hydrazines. In: J. F. Holland and E. Frei (eds.), Cancer Medicine, pp. 806–817. Philadelphia: Lea & Febiger, 1973.
37. Poste, G., and Fidler, I. J. The pathogenesis of cancer metastasis. Nature (Lond.), 283: 139–146, 1980.
38. Raz, A., Hanna, N., and Fidler, I. J. The in vivo isolation of a metastatic tumor cell variant involves selective and not adaptive processes. J. Natl. Cancer Inst., 66:183-189,1981.
39. Raz, A., and Hart, I. R. Murine melanoma. A model for intracranial metastasis. Br. J. Cancer, 42: 331–341, 1980.
40. Retsas, S., Newton, K. A., and Westbury, G. Vindesine as a single agent in the treatment of advanced malignant melanoma. Cancer Chemother. Pharmacol. 2: 257–260, 1979.
41. Schabel, F. M., Jr. Concepts for systemic treatment of micrometastases. Cancer (Phila.), 35: 15–24, 1975.
42. Schabel, F. M., Jr., Griswold, D. P., Jr., Corbett, R. H., Laster, W. R., Jr., Mayo, J. G., and Lloyd, H. H. Testing therapeutic hypotheses in mice and man: Observations on the therapeutic activity against advanced solid tumors of mice treated with anticancer drugs that have demonstrated or have potential clinical utility for treatment of advanced solid tumors of man. Methods Cancer Res., 17: 3–40, 1979.
43. Shoemaker, D. D., Legha, S. S. and Cysyk, R. L. Selective localization of 4’-(9-acridinylamino)-methanesulfon-m-anisidine in B16 melanoma. Pharmacology (Basel), 16: 221–225, 1978.
44. Siracky, J. An approach to the problem of heterogeneity of human tumour-cell populations. Br. J. Cancer, 39: 570–577, 1979.
45. Trope, C. Different sensitivity to cytostatic drugs of primary tumor and metastasis of the Lewis carcinoma. Neoplasma (Bratisl.), 22: 171–180, 1975.
46. Trope, C. Different susceptibilities of tumor cell subpopulations to cytotoxic agents. In: I. J. Fidler and R. J. White (eds.), Design of Models for Testing Cancer Therapeutic Agents. New York: D. Van Nostrand Co., in press, 1981.
47. Trope C. Aspegren, K., Kullander S. and Astedt, B. Heterogeneous response of disseminated human ovarian cancers to cytostatis in vitro. Acta Obstet. Gynecol. Scand., 58; 543–546, 1979.
48. Trope, C., Hakansson, L., and Dencker, H. Heterogeneity of human adenocarcinomas of the colon and the stomach as regards sensitivity to cytostatic drugs. Neoplasma (Bratisl.), 22. 423–430, 1975.
49. Tsuruo, T., Lida, H., Tsukagoshi, S., and Sakurai, Y. Comparison of cytotoxic effect and cellular uptake of 1-/i-o-arabinof uranosylcytosine and its N'-acyl derivatives, using cultured KB cells. Cancer Res., 39. 1063-1070, 1979.
50. Umezawa, H. Studies on bleomycin: Chemistry and the biological action Biomedicine (Paris), 78. 459-475, 1973.
51. Venditti, J. M. Relevance of transplantable animal-tumor systems to the selection of new agents for clinical trial. In: Pharmacological Basis of Cancer Chemotherapy, pp. 245-270. Baltimore: The Williams & Wilkins Co., 1975.